Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06604715
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-18
Brief Title:
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-87562761 in RelapsedRefractory Multiple Myeloma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the recommended phase 2 doses RP2Ds of JNJ-87562761 in Part 1 dose escalation and to determine the safety and tolerability at RP2D in Part 2 dose expansion in participants with multiple myeloma MM whose disease has come back after treatment relapsed or hasnt responded to treatment refractory
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None